Skip to main content
Equibles
AXGN logo

AXGN · Axogen, Inc.

Track AXGN — free

Use AXGN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about AXGN

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$46.44 -2.49 (-5.09%) At close · Aug 20
Market Cap
$2.50B
Shares
53.76M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$46.44 Open$48.45 Day$45.26–49.18 52W close$14.79–50.19 Avg vol 30d1.1M Short int4.1M · 7.6% float · 3.4d Short vol76% Last earningsJul 29, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 29

Up next

Next earnings call
Oct 26, 2026 Est · unconfirmed · in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 29, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Strong Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +29%
      above
      Price vs 50-day avg +6%
      above
      RSI (14) 53
      neutral
      MACD trend Positive
      52-week position 89%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +17%
      trailing
      6-month return +46%
      trailing
      YTD return +42%
      this year
      Relative strength +35%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $44 › 200d $36 — 50d above 200d
      Institutional flow Accumulating
      +13% holders QoQ · +53 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      7.57% of float · ▼ -25.2% MoM · 3.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      251 holders — near 3-yr high, broad support
      Squeeze score 60
      elevated · 0–100
      Fundamentals
      Fair
      Revenue growth +20%
      Y/Y
      Gross margin 74%
      contracting
      EPS growth −48%
      Y/Y
      Free cash flow $-2.9M
      Balance sheet $14.6M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 54%
      annualized · 1-yr
      Max drawdown −19%
      past year
      ATR 4.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 3 of last 3
      Latest guidance · from the 8-K filed Jul 29, 2026
      Full-year revenue · 2026 at least $279M
      prior FY $225.21M midpoint +23.9% Y/Y
      Gross margin · 2026 at least 73%
      Prior guidance period ended · from the 8-K filed Oct 29, 2025
      Revenue · full year at least $222.8M
      Gross margin · full year 73% – 75%
      Guided vs delivered · last 3 settled
      Revenue full year
      guided at least $222.8M
      $225.21M In line
      Revenue full year 2024
      guided $177M – $181M
      $187.34M Beat +4.7%
      Revenue full year 2023
      guided $154M – $159M
      $159.01M Beat +1.6%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Buy
      0 · 3 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +29% Bullish
      Price vs 50-day avg
      +6% Bullish
      RSI (14)
      53 Neutral
      MACD trend
      Positive Bullish
      52-week position
      89% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $44 › 200d $36 — 50d above 200d
      Institutional flow Accumulating
      +13% holders QoQ · +53 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      7.57% of float · ▼ -25.2% MoM · 3.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      251 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $15 Now $46 · 89% Range high $50
      vs 200-day avg +29% vs 50-day avg +6%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted EBITDA - non-GAAP non-GAAP $14.11M Six Months Ended June 30, 2026 —
      Adjusted EBITDA margin - non-GAAP non-GAAP 10.8% Six Months Ended June 30, 2026 —
      Avance® commercial payer coverage 86% Q2 2026 —
      Breast reps 26 Q2 2026 —
      Breast TAM $677M Q2 2026 —
      EBITDA - non-GAAP non-GAAP -$18.35M Six Months Ended June 30, 2026 —
      EBITDA margin - non-GAAP non-GAAP -14% Six Months Ended June 30, 2026 —
      Education programs 9 Q2 2026 —
      Extremities Estimated TAM $2.9B Q2 2026 —
      Extremities reps 126 Q2 2026 —
      Free cash flow non-GAAP $4.07M Six Months Ended June 30, 2026 —
      HiPo accounts 690 Q2 2026 —
      OMF / H&N field-based market development managers 3 Q2 2026 —
      OMF/H&N Estimated TAM $1.2B Q2 2026 —
      Prostate clinical development managers 3 Q2 2026 —
      Prostate TAM $754M Q2 2026 —
      Q2 Adjusted EBITDA* non-GAAP $8.4M Q2 2026 —
      trained surgeon pairs 63 Q2 2026 —
      trained surgeons 155 Q2 2026 —
      US Nerve Care Opportunity $5.6B Q2 2026 —
      Newly covered lives 19.8M full-year 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      AXGN
      Axogen, Inc.
      this stock
      		$2.50B +41.9% +20.2% — 7.6%
      ABT
      Abbott Laboratories
      		 $198.81B -8.9% +5.7% 32.0 1.3%
      SYK
      Stryker Corp
      		 $127.26B -6.8% +11.2% 34.4 2.2%
      MDT
      Medtronic plc
      		 $120.49B -3.9% +8.4% 25.2 1.4%
      BSX
      Boston Scientific Corp
      		 $71.55B -48.2% +12.5% 20.0 1.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      251
      % held
      97.8%
      Net QoQ
      +2.6M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      227
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      4.1M
      Days to cover
      3.4d
      Change
      -1.4M sh
      View
      Short Volume
      Short vol %
      76%
      As of
      Aug 20, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      20.3K
      Value
      $838.8K
      As of
      Jul 30, 2026
      View
      Off-Exchange
      Off-exchange %
      37.1%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      Donna Shalala
      Amount
      $1.0K–$15.0K
      Traded
      Jun 24, 2019
      View
      Financials
      Financials
      Revenue (FY)
      $225.2M
      Net income (FY)
      $-15.7M
      EPS diluted
      $-0.34
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 29, 2026
      This year
      10
      View
      Proposed Sales
      Value
      $643.9K
      Shares
      13.4K
      Filed
      Aug 11, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 29, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      AXGN -3.4% +16.9% +46.4% +10.0% +41.9%
      SPY -2.0% +3.3% +11.2% +2.1% +11.8%
      vs SPY -1.4% +13.6% +35.2% +7.9% +30.1%
      Key facts CIK 805928 CUSIP 05463X106 13F (30d) 234 filings 231 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)